Sobi and Apellis Pharmaceuticals report promising results for pegcetacoplan in phase 2 NOBLE study
Sobi and Apellis Pharmaceuticals, Inc. have announced encouraging one-year outcomes from the phase 2 NOBLE study, investigating the efficacy of systemic pegcetacoplan for treating post-transplant ... Read More
Apellis to submit NDA for intravitreal pegcetacoplan to FDA in H1 2022
Apellis Pharmaceuticals said that it is on track to submit a new drug application (NDA) for its intravitreal pegcetacoplan to the US Food and Drug ... Read More
Positive results for pegcetacoplan in C3 glomerulopathy treatment: A step forward in kidney disease research
Apellis Pharmaceuticals has unveiled significant findings from its Phase 2 DISCOVERY clinical trial, offering a ray of hope for patients suffering from C3 glomerulopathy (C3G), ... Read More